Logo image of COUR.PA

COURTOIS-R (COUR.PA) Stock Fundamental Analysis

EPA:COUR - Euronext Paris - Matif - FR0000065393 - Common Stock - Currency: EUR

122  +8 (+7.02%)

Fundamental Rating

2

Taking everything into account, COUR scores 2 out of 10 in our fundamental rating. COUR was compared to 70 industry peers in the Real Estate Management & Development industry. While COUR seems to be doing ok healthwise, there are quite some concerns on its profitability. COUR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year COUR has reported negative net income.
In the past year COUR has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: COUR reported negative net income in multiple years.
In multiple years COUR reported negative operating cash flow during the last 5 years.
COUR.PA Yearly Net Income VS EBIT VS OCF VS FCFCOUR.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M

1.2 Ratios

Looking at the Return On Assets, with a value of -1.13%, COUR is in line with its industry, outperforming 50.00% of the companies in the same industry.
Looking at the Return On Equity, with a value of -1.54%, COUR is in line with its industry, outperforming 54.29% of the companies in the same industry.
Industry RankSector Rank
ROA -1.13%
ROE -1.54%
ROIC N/A
ROA(3y)0.62%
ROA(5y)0.6%
ROE(3y)0.77%
ROE(5y)0.86%
ROIC(3y)N/A
ROIC(5y)N/A
COUR.PA Yearly ROA, ROE, ROICCOUR.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1 2 3 4

1.3 Margins

COUR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COUR.PA Yearly Profit, Operating, Gross MarginsCOUR.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

More info and screens

6

2. Health

2.1 Basic Checks

COUR does not have a ROIC to compare to the WACC, probably because it is not profitable.
COUR has about the same amout of shares outstanding than it did 1 year ago.
COUR has about the same amout of shares outstanding than it did 5 years ago.
Compared to 1 year ago, COUR has an improved debt to assets ratio.
COUR.PA Yearly Shares OutstandingCOUR.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20K 40K 60K
COUR.PA Yearly Total Debt VS Total AssetsCOUR.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

COUR has an Altman-Z score of 2.27. This is not the best score and indicates that COUR is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.27, COUR belongs to the top of the industry, outperforming 91.43% of the companies in the same industry.
A Debt/Equity ratio of 0.03 indicates that COUR is not too dependend on debt financing.
COUR has a Debt to Equity ratio of 0.03. This is amongst the best in the industry. COUR outperforms 90.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 2.27
ROIC/WACCN/A
WACC6.74%
COUR.PA Yearly LT Debt VS Equity VS FCFCOUR.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 5.65 indicates that COUR has no problem at all paying its short term obligations.
COUR's Current ratio of 5.65 is amongst the best of the industry. COUR outperforms 90.00% of its industry peers.
A Quick Ratio of 2.83 indicates that COUR has no problem at all paying its short term obligations.
COUR's Quick ratio of 2.83 is amongst the best of the industry. COUR outperforms 85.71% of its industry peers.
Industry RankSector Rank
Current Ratio 5.65
Quick Ratio 2.83
COUR.PA Yearly Current Assets VS Current LiabilitesCOUR.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

COUR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -26.68%.
The Revenue has grown by 52.77% in the past year. This is a very strong growth!
COUR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -10.74% yearly.
EPS 1Y (TTM)-26.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-169.07%
Revenue 1Y (TTM)52.77%
Revenue growth 3Y-32.41%
Revenue growth 5Y-10.74%
Sales Q2Q%5.01%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COUR.PA Yearly Revenue VS EstimatesCOUR.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

COUR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COUR.PA Price Earnings VS Forward Price EarningsCOUR.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COUR.PA Per share dataCOUR.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100 150 200 250

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

2

5. Dividend

5.1 Amount

COUR has a Yearly Dividend Yield of 2.02%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 7.36, COUR has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.41, COUR has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 2.02%

5.2 History

The dividend of COUR decreases each year by -8.18%.
Dividend Growth(5Y)-8.18%
Div Incr Years0
Div Non Decr Years0
COUR.PA Yearly Dividends per shareCOUR.PA Yearly Dividends per shareYearly Dividends per share 2019 2023 0.5 1 1.5 2 2.5

5.3 Sustainability

DP0%
EPS Next 2YN/A
EPS Next 3YN/A
COUR.PA Yearly Income VS Free CF VS DividendCOUR.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M

More info and screens

COURTOIS-R

EPA:COUR (5/12/2025, 7:00:00 PM)

122

+8 (+7.02%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners80.73%
Ins Owner ChangeN/A
Market Cap8.54M
Analysts78.82
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.02%
Yearly Dividend2.75
Dividend Growth(5Y)-8.18%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.96
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-3.96
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-8.53
FCFYN/A
OCF(TTM)-8.23
OCFYN/A
SpS20.47
BVpS267.73
TBVpS267.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.13%
ROE -1.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)0.62%
ROA(5y)0.6%
ROE(3y)0.77%
ROE(5y)0.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.65
Quick Ratio 2.83
Altman-Z 2.27
F-Score3
WACC6.74%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-26.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-169.07%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)52.77%
Revenue growth 3Y-32.41%
Revenue growth 5Y-10.74%
Sales Q2Q%5.01%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-108.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.09%
OCF growth 3YN/A
OCF growth 5YN/A